Jiarui Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jiarui Zhou has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Adam Corrigan
Phenomics, Data Sciences & Quantitative Biology, R&D AstraZeneca, Cambridge, UK
1 shared publication - Alfie S. Carter
Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK
1 shared publication - Amy Pointon
Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, United Kingdom
1 shared publication - Andrew R. Hall
The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London WC1E 6HX, UK
1 shared publication - Delyan P. Ivanov
High-Throughput Screening, R&D, AstraZeneca, Alderley Park, UK
1 shared publication - Hongbin Yang
Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Cambridge, UK
1 shared publication
Latest Publications
- Open Access
- 28 June 2024
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 40 (1) , 1-19
Computational approaches identify a transcriptomic fingerprint of drug-induced structural cardiotoxicity
Structural cardiotoxicity (SCT) presents a high-impact risk that is poorly tolerated in drug discovery unless significant benefit is anticipated. Therefore, we aimed to improve the mechanistic understanding of SCT. First, we combined machine learning methods with a modified calcium transient assay in human-induced pluripotent stem cell-derived cardiomyocytes to identify nine parameters that could predict SCT. Next, we applied transcriptomic profiling to human cardiac microtissues exposed to structural and non-structural cardiotoxins. Fifty-two genes expressed across the three main cell types in the heart (cardiomyocytes, endothelial cells, and fibroblasts) were prioritised in differential expression and network clustering analyses and could be linked to known mechanisms of SCT. This transcriptomic fingerprint may prove useful for generating strategies to mitigate SCT risk in early drug discovery. Graphical Abstract
- 28 June 2024
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 40 (1) , 1-19
Open AccessComputational approaches identify a transcriptomic fingerprint of drug-induced structural cardiotoxicity
Structural cardiotoxicity (SCT) presents a high-impact risk that is poorly tolerated in drug discovery unless significant benefit is anticipated. Therefore, we aimed to improve the mechanistic understanding of SCT. First, we combined machine learning methods with a modified calcium transient assay in human-induced pluripotent stem cell-derived cardiomyocytes to identify nine parameters that could predict SCT. Next, we applied transcriptomic profiling to human cardiac microtissues exposed to structural and non-structural cardiotoxins. Fifty-two genes expressed across the three main cell types in the heart (cardiomyocytes, endothelial cells, and fibroblasts) were prioritised in differential expression and network clustering analyses and could be linked to known mechanisms of SCT. This transcriptomic fingerprint may prove useful for generating strategies to mitigate SCT risk in early drug discovery. Graphical Abstract